In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
|Expert Interviews|August 20, 2019
Jennifer Zilka, Group Vice President of Good Neighbor Pharmacy’s Field Programs and Services
Advertisement
Good Neighbor Pharmacy streamlined their approach to make it easier for their customers to access and navigate their industry-leading solutions and programs, which are now organized within four value centers.
Advertisement
Related to this article
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
3
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
4
Pharmacies Face Persistent MFP Cash Crunch Amid PBM, 340B Shifts
5